Alto Neuroscience (NYSE:ANRO) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Alto Neuroscience (NYSE:ANRO) posted its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05, Zacks reports.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $4.61 on Friday. The stock’s 50-day simple moving average is $10.02 and its 200-day simple moving average is $11.46. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 19.85. Alto Neuroscience has a fifty-two week low of $3.61 and a fifty-two week high of $24.00.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ANRO. Stifel Nicolaus lowered their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Rodman & Renshaw cut Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.